Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy.
Related Posts
The Killer Stalking Sri Lanka’s Men
Climate change and contaminated water have combined to create an epidemic of kidney disease.
FDA Moves Forward With Last-Minute Push to Cut Nicotine Levels in Cigarettes
In the final days of the Biden administration, the F.D.A. is moving ahead with a proposal to require companies to…
What Nearly Brainless Rodents Know About Weight Loss and Hunger
Studies in neuroscience with applications to humans offer clues about what makes us start eating, and when we stop.